Bristol Pravachol pediatric approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb's Pravachol (pravastatin) is approved Oct. 29 for use in pediatric patients eight years or older with heterozygous familial hypercholesterolemia. Bristol receives six months of pediatric exclusivity, extending protection against generics through April 200